Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.

Duran GE, Derdau V, Weitz D, Philippe N, Blankenstein J, Atzrodt J, Sémiond D, Gianolio DA, Macé S, Sikic BI.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1095-1103. doi: 10.1007/s00280-018-3572-1. Epub 2018 Apr 19.

PMID:
29675746
2.

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T.

J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.

PMID:
28463630
3.

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.

Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI.

Br J Cancer. 2017 May 9;116(10):1318-1328. doi: 10.1038/bjc.2017.102. Epub 2017 Apr 11.

4.

Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1.

Dubey R, Lebensohn AM, Bahrami-Nejad Z, Marceau C, Champion M, Gevaert O, Sikic BI, Carette JE, Rohatgi R.

Cancer Res. 2016 Oct 1;76(19):5810-5821. Epub 2016 Aug 8.

5.

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Rosen LS, LoRusso P, Ma WW, Goldman JW, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Hsieh HJ, Chan IT, Sikic BI.

Invest New Drugs. 2016 Oct;34(5):604-13. doi: 10.1007/s10637-016-0374-3. Epub 2016 Jul 16.

PMID:
27424159
6.

Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.

Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker R, Čufer T, Bešlija S, Eniu A, Todorović V, Kubáčková K, Kurteva G, Tomašević Z, Sallaku A, Smichkoska S, Bajić Ž, Šikić BI.

Oncologist. 2016 Oct;21(10):1183-1190. Epub 2016 Jul 8.

7.

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.

Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B.

PLoS One. 2016 Feb 17;11(2):e0149183. doi: 10.1371/journal.pone.0149183. eCollection 2016.

8.

The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.

Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI.

Mol Oncol. 2015 Oct;9(8):1678-93. doi: 10.1016/j.molonc.2015.04.015. Epub 2015 May 16.

9.

Mechanisms of resistance to cabazitaxel.

Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI.

Mol Cancer Ther. 2015 Jan;14(1):193-201. doi: 10.1158/1535-7163.MCT-14-0155. Epub 2014 Nov 21.

10.

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI.

Mol Oncol. 2014 Oct;8(7):1231-9. doi: 10.1016/j.molonc.2014.03.016. Epub 2014 Apr 18.

11.

Identification of ovarian cancer driver genes by using module network integration of multi-omics data.

Gevaert O, Villalobos V, Sikic BI, Plevritis SK.

Interface Focus. 2013 Aug 6;3(4):20130013. doi: 10.1098/rsfs.2013.0013. Erratum in: Interface Focus. 2014 Jun 6;4(3):20140023.

12.

Clinical trial designs for testing biomarker-based personalized therapies.

Lai TL, Lavori PW, Shih MC, Sikic BI.

Clin Trials. 2012 Apr;9(2):141-54. doi: 10.1177/1740774512437252. Epub 2012 Mar 7.

13.

Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Chen KG, Sikic BI.

Clin Cancer Res. 2012 Apr 1;18(7):1863-9. doi: 10.1158/1078-0432.CCR-11-1590. Epub 2012 Feb 16. Review.

14.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL.

Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3. Epub 2012 Feb 14.

15.

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.

Cabebe EC, Fisher GA, Sikic BI.

Invest New Drugs. 2012 Jun;30(3):1082-7. doi: 10.1007/s10637-011-9656-y. Epub 2011 Mar 15.

PMID:
21404105
16.

NFKBIA deletion in glioblastomas.

Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR 4th.

N Engl J Med. 2011 Feb 17;364(7):627-37. doi: 10.1056/NEJMoa1006312. Epub 2010 Dec 22.

17.

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.

Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI.

Mol Cancer Ther. 2010 Nov;9(11):2970-81. doi: 10.1158/1535-7163.MCT-10-0780. Epub 2010 Nov 9.

18.

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.

Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI.

Invest New Drugs. 2011 Oct;29(5):971-7. doi: 10.1007/s10637-010-9416-4. Epub 2010 Mar 28.

PMID:
20349264
19.

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV.

Pediatr Blood Cancer. 2010 May;54(5):694-702. doi: 10.1002/pbc.22366.

20.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW.

Ann Oncol. 2010 Feb;21(2):376-81. doi: 10.1093/annonc/mdp292. Epub 2009 Jul 24.

21.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

22.

A network model of a cooperative genetic landscape in brain tumors.

Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI.

JAMA. 2009 Jul 15;302(3):261-75. doi: 10.1001/jama.2009.997.

23.

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI.

Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23.

PMID:
19108889
24.

A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.

Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI.

Clin Cancer Res. 2008 Nov 1;14(21):7074-9. doi: 10.1158/1078-0432.CCR-08-1014.

25.

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI.

Leuk Res. 2009 Jun;33(6):769-74. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30.

PMID:
18976810
26.

Genomics of childhood leukemias: the virtue of complexity.

Sikic BI, Tibshirani R, Lacayo NJ.

J Clin Oncol. 2008 Sep 20;26(27):4367-8. doi: 10.1200/JCO.2008.16.4285. No abstract available.

PMID:
18802145
27.

Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?

Chan JK, Ueda SM, Sugiyama VE, Stave CD, Shin JY, Monk BJ, Sikic BI, Osann K, Kapp DS.

J Clin Oncol. 2008 Mar 20;26(9):1511-8. doi: 10.1200/JCO.2007.14.8874. Epub 2008 Feb 19.

PMID:
18285603
28.

Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.

Juric D, Bredel C, Sikic BI, Bredel M.

Methods Mol Biol. 2007;377:187-202. Review.

PMID:
17634618
29.

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI.

J Clin Oncol. 2007 Apr 10;25(11):1341-9. Epub 2007 Feb 20.

PMID:
17312329
30.

A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.

Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC; Eastern Cooperative Oncology Group.

Cancer Invest. 2006 Nov;24(7):677-81.

PMID:
17118777
31.

Multidrug resistance and stem cells in acute myeloid leukemia.

Sikic BI.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3231-2. Review. No abstract available.

32.

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.

Cho CD, Fisher GA, Halsey J, Sikic BI.

Invest New Drugs. 2006 Mar;24(2):117-23.

PMID:
16683204
33.

Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein.

DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV.

Leukemia. 2006 Mar;20(3):426-32.

PMID:
16424866
34.

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI.

Genes Chromosomes Cancer. 2006 Apr;45(4):365-74.

PMID:
16382445
35.

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI.

J Clin Oncol. 2006 Jan 10;24(2):274-87. Epub 2005 Dec 19.

PMID:
16365179
36.

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17763-8. Epub 2005 Nov 23.

37.

Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H; Pediatric Oncology Group.

Blood. 2006 Feb 15;107(4):1315-24. Epub 2005 Oct 27.

38.

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI.

Cancer Res. 2005 Oct 15;65(20):9388-97.

39.

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.

Cancer Res. 2005 Oct 1;65(19):8679-89.

40.

Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.

Wakelee HA, Sikic BI.

Clin Lung Cancer. 2005 Sep;7 Suppl 1:S6-12. Review.

PMID:
16159420
41.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.

Invest New Drugs. 2005 Oct;23(5):467-77.

PMID:
16133798
42.

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.

Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI.

Ann Oncol. 2005 Dec;16(12):1968-73. Epub 2005 Aug 26.

PMID:
16126736
43.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI.

J Clin Oncol. 2005 Aug 20;23(24):5613-9.

PMID:
16110021
44.

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.

Cancer Res. 2005 May 15;65(10):4088-96.

45.

Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA.

Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR, Sikic BI.

J Mol Diagn. 2005 May;7(2):171-82.

46.

Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.

Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI.

Bull Cancer. 2004 May;91(5):E81-112.

47.

A method for detecting and correcting feature misidentification on expression microarrays.

Tu IP, Schaner M, Diehn M, Sikic BI, Brown PO, Botstein D, Fero MJ.

BMC Genomics. 2004 Sep 9;5:64.

48.

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.

Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV.

Blood. 2004 Nov 1;104(9):2646-54. Epub 2004 Jul 13.

50.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM.

J Clin Oncol. 2004 Mar 15;22(6):1078-86. Erratum in: J Clin Oncol. 2004 Jul 1;22(13):2747.

Supplemental Content

Loading ...
Support Center